Reynders Mcveigh Capital Management Has Lowered Biogen (BIIB) Holding; Standard General LP Has Lifted By $5.69 Million Its National Cinemedia (NCMI) Stake

June 19, 2018 - By Sheldon Barnett

National CineMedia, Inc. (NASDAQ:NCMI) Logo

Standard General Lp increased National Cinemedia Inc (NCMI) stake by 8.59% reported in 2018Q1 SEC filing. Standard General Lp acquired 1.14M shares as National Cinemedia Inc (NCMI)’s stock declined 6.87%. The Standard General Lp holds 14.39M shares with $74.67M value, up from 13.25 million last quarter. National Cinemedia Inc now has $1.28B valuation. The stock increased 5.15% or $0.39 during the last trading session, reaching $7.99. About 911,520 shares traded or 16.57% up from the average. National CineMedia, Inc. (NASDAQ:NCMI) has declined 3.75% since June 19, 2017 and is downtrending. It has underperformed by 16.32% the S&P500. Some Historical NCMI News: ; 12/03/2018 – NATIONAL CINEMEDIA INC NCMI.O SEES FY 2018 REVENUE $425 MLN TO $445 MLN; 12/03/2018 – NATIONAL CINEMEDIA SEES FY REV. $425.0M TO $445.0M; 12/03/2018 – NATIONAL CINEMEDIA CUTS QTR DIV TO 17C/SHR FROM 22C, EST. 22C; 22/05/2018 – National CineMedia Presenting at Conference Tomorrow; 07/05/2018 – NATIONAL CINEMEDIA INC – REAFFIRMS FULL YEAR 2018 OUTLOOK; 12/03/2018 – National CineMedia Sees 2018 Revenue Flat to Up 4.5%; 12/03/2018 – NATIONAL CINEMEDIA 4Q REV. $140.7M, EST. $144.5M; 21/04/2018 – DJ National CineMedia Inc, Inst Holders, 1Q 2018 (NCMI); 14/03/2018 – NATIONAL CINEMEDIA FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC; 15/05/2018 – National CineMedia Rises for 8 Days: Longest Streak Since IPO

Reynders Mcveigh Capital Management Llc decreased Biogen Inc (BIIB) stake by 62.95% reported in 2018Q1 SEC filing. Reynders Mcveigh Capital Management Llc sold 6,767 shares as Biogen Inc (BIIB)’s stock declined 1.31%. The Reynders Mcveigh Capital Management Llc holds 3,983 shares with $14.55M value, down from 10,750 last quarter. Biogen Inc now has $61.80 billion valuation. The stock increased 1.29% or $3.74 during the last trading session, reaching $292.86. About 915,978 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 13.14% since June 19, 2017 and is uptrending. It has outperformed by 0.57% the S&P500. Some Historical BIIB News: ; 17/04/2018 – T Rowe Price Growth Adds Disney, Exits Biogen, Cuts Apple; 05/04/2018 – Biogen and Samsung Bioepis Agree to Settlement With AbbVie Allowing Commercialization of IMRALDI(TM) (Adalimumab Biosimilar) in Europe; 20/04/2018 – Biogen: Will Have Option to License Therapies From Collaboration, Will Be Responsible for Their Development and Commercialization; 17/04/2018 – Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and; 27/04/2018 – Biogen Closes Above 50-Day Moving Average: Technicals; 23/04/2018 – Biogen’s Tecfidera Falls After 1-Wk Rise, Avonex Declines: MS; 24/04/2018 – BIOGEN INC – QTRLY PLEGRIDY REVENUE OF $100 MLN VS. $112 MLN REPORTED LAST YEAR; 24/04/2018 – Biogen Idec 1Q Net $1.2B; 01/05/2018 – Biogen Will Pay $50 Million To Reduce Royalties On Alzheimer’s Disease Drug — MarketWatch; 01/05/2018 – Biogen Gets 5% Reduction in Original Royalty Rates on Potential Commercial Sales of Aducanumab

Among 12 analysts covering National CineMedia Inc (NASDAQ:NCMI), 5 have Buy rating, 1 Sell and 6 Hold. Therefore 42% are positive. National CineMedia Inc had 29 analyst reports since August 7, 2015 according to SRatingsIntel. On Wednesday, February 1 the stock rating was downgraded by Credit Suisse to “Underperform”. The company was maintained on Tuesday, November 8 by Benchmark. The stock has “Outperform” rating by FBR Capital on Tuesday, November 10. The firm has “Neutral” rating by B. Riley & Co given on Tuesday, November 7. The firm has “Sell” rating by J.P. Morgan given on Wednesday, November 8. The company was downgraded on Wednesday, July 20 by Stifel Nicolaus. The rating was upgraded by FBR Capital to “Buy” on Monday, March 19. The firm earned “Buy” rating on Tuesday, August 8 by B. Riley & Co. The firm earned “Buy” rating on Monday, March 19 by B. Riley & Co. M Partners maintained it with “Neutral” rating and $16 target in Tuesday, November 10 report.

More news for National CineMedia, Inc. (NASDAQ:NCMI) were recently published by:, which released: “Here’s How National CineMedia, Inc. Stock Gained 30% Last Month” on June 14, 2018.‘s article titled: “NCMI, Standard General in deal to add board member” and published on June 01, 2018 is yet another important article.

Since March 16, 2018, it had 3 insider buys, and 1 insider sale for $1.41 million activity. Shares for $1.37 million were bought by Standard General L.P. on Wednesday, March 21. AMC STARPLEX – LLC sold $7.23 million worth of stock or 1.00 million shares.

Investors sentiment increased to 1.13 in 2018 Q1. Its up 0.07, from 1.06 in 2017Q4. It is positive, as 14 investors sold NCMI shares while 39 reduced holdings. 25 funds opened positions while 35 raised stakes. 64.03 million shares or 0.77% more from 63.54 million shares in 2017Q4 were reported. Swiss Retail Bank, Switzerland-based fund reported 136,500 shares. Stone Ridge Asset Mngmt Ltd Liability Corporation stated it has 0.01% in National CineMedia, Inc. (NASDAQ:NCMI). New York State Common Retirement Fund holds 0% or 61,700 shares. Prelude Capital Mngmt Ltd Liability Company accumulated 18,619 shares or 0.01% of the stock. 13,461 were accumulated by Jpmorgan Chase Communications. Hbk Invs Lp holds 28,300 shares or 0% of its portfolio. Oaktree Mngmt LP holds 2.82 million shares. Panagora Asset Management holds 0.01% or 600,032 shares. Alliancebernstein LP invested 0% in National CineMedia, Inc. (NASDAQ:NCMI). Spark Investment Mgmt Ltd Liability Corp holds 138,000 shares. Us Bank De invested in 0% or 703 shares. Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in National CineMedia, Inc. (NASDAQ:NCMI). Federated Invsts Pa stated it has 0% in National CineMedia, Inc. (NASDAQ:NCMI). Georgia-based Invesco Ltd has invested 0% in National CineMedia, Inc. (NASDAQ:NCMI). Gabelli Funds Llc has 79,500 shares.

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Biogen Idec Inc. had 133 analyst reports since July 23, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of BIIB in report on Thursday, January 25 with “Buy” rating. Oppenheimer initiated the shares of BIIB in report on Wednesday, November 8 with “Buy” rating. Mizuho maintained the shares of BIIB in report on Sunday, February 4 with “Buy” rating. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by UBS on Monday, June 19. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by Credit Suisse on Thursday, January 25. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by RBC Capital Markets on Wednesday, April 4. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by Robert W. Baird on Friday, March 11. The firm has “Buy” rating given on Tuesday, August 25 by Cowen & Co. As per Tuesday, July 11, the company rating was reinitiated by Jefferies. The stock of Biogen Inc. (NASDAQ:BIIB) has “Market Perform” rating given on Wednesday, September 13 by BMO Capital Markets.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: which released: “Here’s Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle” on June 18, 2018, also with their article: “PTC Therapeutics’ risdiplam shows positive effect in SMA study; shares up 36% premarket” published on June 18, 2018, published: “Alzheimer’s Disease: A History Of Drug Failures” on June 19, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: and their article: “Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today” published on June 18, 2018 as well as‘s news article titled: “Biogen Appoints Daniel Karp as EVP, Corporate Development” with publication date: May 31, 2018.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on July, 24. They expect $5.22 earnings per share, up 3.57% or $0.18 from last year’s $5.04 per share. BIIB’s profit will be $1.10 billion for 14.03 P/E if the $5.22 EPS becomes a reality. After $6.05 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -13.72% negative EPS growth.

National CineMedia, Inc. (NASDAQ:NCMI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: